Get the Stockscreener App
4.78
7.18%
-0.37
Pre-market:
5.00
0.22
+4.60%
Trisalus Life Sciences Inc stock is traded at $4.78, with a volume of 27,585.
It is down -7.18% in the last 24 hours and up +14.35% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$5.15
Open:
$5.19
24h Volume:
27,585
Relative Volume:
0.76
Market Cap:
$145.76M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-2.728
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
-4.02%
1M Performance:
+14.35%
6M Performance:
-12.29%
1Y Performance:
-45.06%
1-Day Range:
$4.72
$5.19
1-Week Range:
$4.72
$5.19
52-Week Range:
$3.50
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.78 | 145.76M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus's TriNav System Shows Breakthrough 227% Increase in Liver Cancer Drug Delivery Efficacy - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
TLSITriSalus Life Sciences, Inc. Latest Stock News & Market Updates - StockTitan
TriSalus Announces Leadership Changes and New Incentive Program - TipRanks
TriSalus Life Sciences names new finance chief - MSN
TriSalus Has Several Leadership Changes - MPO-mag
TriSalus Life Sciences reshuffles executive team - Investing.com
TriSalus Life Sciences Taps James Young as CFO - MarketWatch
TriSalus Life Sciences Strengthens Executive Team with Strategic Leadership Appointments for 2025 - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in December - MarketBeat
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of TriSalus Life Sciences (TLSI) with Overweight Recommendation - MSN
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Trisalus life sciences officer sells $1,394 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in Stock - MarketBeat
Frankenius equity AB acquires shares in Trisalus Life Sciences for $249,998 - Investing.com
Trisalus life sciences officer sells $1,394 in stock - Investing.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Cantor Fitzgerald - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus Price Target from Analysts - Defense World
Great-West Lifeco Inc. (TSE:GWO) Receives C$47.63 Consensus Price Target from Analysts - Defense World
Analysts Set Forward Air Co. (NASDAQ:FWRD) PT at $39.25 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Safe Bulkers (NYSE:SB) versus Euronav (NYSE:CMBT) Financial Survey - Defense World
Stock Traders Buy High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA) - Defense World
TriSalus Life Sciences Forms Strategic Partnership With Geo-Med - MPO-mag
TriSalus Expands PEDD Portfolio - MPO-mag
Cantor Fitzgerald Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - MarketBeat
Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $12.08 - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Increase in Short Interest - MarketBeat
TriSalus Life Sciences director sells $110,700 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences director sells $110,700 in stock - Investing.com India
Director Arjun Desai Sells 30,000 Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus.com
Liver Cancer Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight - EIN News
Northland Capmk Brokers Increase Earnings Estimates for TLSI - MarketBeat
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK
Friday's Insider Moves: Top Executives Make Notable Stock Transactions - Investing.com India
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World
Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada
TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Revenue Soars 42% in Q3, Expands into $375M Market | TLSI Stock News - StockTitan
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):